Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficlatuzumab + azacitidine + venetoclax
- Development stage
- Phase 3
- Lead developer
- AVEO Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Ficlatuzumab + azacitidine + venetoclax is an investigational combination regimen being evaluated for the treatment of newly diagnosed, untreated acute myeloid leukemia (AML) in patients aged 60 years or older who are unfit for intensive chemotherapy. The regimen combines ficlatuzumab, a first-in-class humanized IgG1 monoclonal antibody targeting hepatocyte growth factor (HGF), with the standard-of-care backbone of azacitidine (a hypomethylating agent) and venetoclax (a BCL-2 inhibitor). By targeting HGF, ficlatuzumab inhibits the HGF/c-Met signaling pathway, which is implicated in leukemia cell survival, expansion, and resistance to therapy. The combination is being studied in a Phase 1b/2 clinical trial as a sub-study of Blood Cancer United's (formerly The Leukemia & Lymphoma Society) Beat AML Master Clinical Trial, in collaboration with AVEO Oncology.
- Other names
- ficlatuzumab + venetoclax + azacitidineficlatuzumab, azacitidine and venetoclaxficlatuzumab, azacitidine, and venetoclax
02
Targets
BAKBAX (Apoptosis regulator BAX)BIMDNMT1 (DNA (cytosine-5)-methyltransferase 1)HGF (Hepatocyte growth factor)MET (Mesenchymal-epithelial transition factor receptor)BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on ficlatuzumab + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficlatuzumab + azacitidine + venetoclax.